Genmab A/S (GNMSF) Share-based Compensation (2024 - 2026)
Genmab A's (GNMSF) quarterly Share-based Compensation came in at $49.0 million in Q1 2026, up 96.0% YoY from $25.0 million in Q1 2025, and down 46.74% on a QoQ basis from $92.0 million in Q3 2025.
Genmab A/S (GNMSF) Share-based Compensation (2024 - 2026) Analysis & Trends
Genmab A (GNMSF) has 3 years of Share-based Compensation data on file, last reported at $49.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 96.0% year-over-year to $49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $224.0 million (up 25.84% YoY) and the FY2025 annual result came in at $128.0 million, up 21.9% from the prior year.
- Share-based Compensation fell to $49.0 million in Q1 2026, from $92.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $92.0 million in Q3 2025 to a low of $24.0 million in Q1 2024.
- A 3-year average of $53.9 million and a median of $51.0 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation grew 4.17% — and 2026, when it jumped 96.0%.
- Tracing GNMSF's Share-based Compensation over 3 years: stood at $78.0 million in 2024, then climbed by 17.95% to $92.0 million in 2025, then plunged by 46.74% to $49.0 million in 2026.
- The last three Share-based Compensation figures came in at $49.0 million (Q1 2026), $92.0 million (Q3 2025), and $58.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.00 Mn |
| Mar 31, 2026 | 49.00 Mn |
| Sep 30, 2025 | 92.00 Mn |
| Sep 30, 2025 | 92.00 Mn |
| Jun 30, 2025 | 58.00 Mn |
| Jun 30, 2025 | 58.00 Mn |
| Mar 31, 2025 | 25.00 Mn |
| Mar 31, 2025 | 25.00 Mn |
| Sep 30, 2024 | 78.00 Mn |
| Sep 30, 2024 | 78.00 Mn |
| Jun 30, 2024 | 51.00 Mn |
| Jun 30, 2024 | 51.00 Mn |
| Mar 31, 2024 | 24.00 Mn |
| Mar 31, 2024 | 24.00 Mn |